Hypofractionated proton beam therapy regimen feasible for glioblastoma in older patients
A short course of hypofractionated proton beam therapy given alongside temozolomide may offer an improvement in overall survival for patients aged 65 years and older with a new diagnosis of glioblastoma, suggesting findings from a “hypothesis-generating” study.
